- Home
- QNRX vs HKPD Comparison
QNRX vs HKPD Comparison
Compare QNRX & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNRX | HKPD |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 10.6M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | QNRX | HKPD |
|---|---|---|
| Price | $11.50 | $0.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 42.5K | 40.6K |
| Earning Date | 11-06-2025 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $20,313,818.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.72 |
| 52 Week Low | $5.01 | $0.68 |
| 52 Week High | $41.80 | $3.79 |
Technical Indicators
Market Signals| Indicator | QNRX | HKPD |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 44.42 |
| Support Level | $10.88 | $0.75 |
| Resistance Level | $14.25 | $0.83 |
| Average True Range (ATR) | 0.96 | 0.07 |
| MACD | -0.27 | 0.01 |
| Stochastic Oscillator | 9.95 | 43.47 |
Price Performance
Historical ComparisonAbout QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.